Primary radiotherapy vs conservative management for localized prostate cancer-a population-based study

被引:7
|
作者
Lu-Yao, G. L. [1 ,2 ]
Kim, S. [2 ,3 ]
Moore, D. F. [2 ,4 ]
Shih, W. [2 ,4 ]
Lin, Y. [2 ,4 ]
DiPaola, R. S. [1 ,2 ]
Shen, S. [2 ]
Zietman, A. [5 ]
Yao, S-L [1 ,2 ]
机构
[1] Rutgers State Univ, Robert Wood Johnson Med Sch, Dept Med, Piscataway, NJ 08854 USA
[2] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA
[3] Rutgers State Univ, Robert Wood Johnson Med Sch, Dept Radiat Oncol, New Brunswick, NJ 08903 USA
[4] Rutgers State Univ, Sch Publ Hlth, Dept Biostat, Piscataway, NJ USA
[5] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA
关键词
ANDROGEN-DEPRIVATION THERAPY; LONG-TERM SURVIVAL; RADICAL PROSTATECTOMY; RADIATION-THERAPY; PHASE-III; RISK; OUTCOMES; MEN;
D O I
10.1038/pcan.2015.30
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: Radiotherapy is the most common curative cancer therapy used for elderly patients with localized prostate cancer. However, the effectiveness of this approach has not been established. The purpose of this study is to evaluate the long-term outcomes of primary radiotherapy compared with conservative management in order to facilitate treatment decisions. METHOD: This population-based study consisted of 57 749 patients with T1-T2 prostate cancers diagnosed during 1992-2007. We utilized an instrumental variable (IV) analytical approach with competing risk models to evaluate the outcomes of primary radiotherapy vs conservative management. The IV was comprised of combined health service areas with high-and low-use areas corresponding to the top and bottom tertile in radiotherapy usage rates. RESULTS: In patients with low-/intermediate-risk prostate cancer, 10-year prostate cancer-specific and overall survival was similar in high-and low-radiotherapy use areas (96.1 vs 95.4% and 56.6 vs 56.3%, respectively). In patients with high-risk disease, however, areas with high-radiotherapy use had a higher 10-year cancer-specific survival (90.2 vs 88.1%, difference 2.1%; 95% CI 0.3-4.0%) and 10-year overall survival (53.3 vs 50.2%, difference 3.1%; 95% CI 1.3-6.3%). Results were similar irrespective of the type of radiotherapy used. To assess the robustness of our choice of IV, we repeated the IV analytical approach using different IVs (using the median utilization rate as the cutoff) and found the results to be similar. CONCLUSIONS: Among men 465 years of age, the benefit of primary radiotherapy for localized disease is largely confined to patients with high-risk prostate cancer (Gleason scores 7-10).
引用
收藏
页码:317 / 324
页数:8
相关论文
共 50 条
  • [1] Primary radiotherapy vs conservative management for localized prostate cancer—a population-based study
    G L Lu-Yao
    S Kim
    D F Moore
    W Shih
    Y Lin
    R S DiPaola
    S Shen
    A Zietman
    S-L Yao
    [J]. Prostate Cancer and Prostatic Diseases, 2015, 18 : 317 - 324
  • [2] RADIOTHERAPY VERSUS CONSERVATIVE MANAGEMENT IN ELDERLY PATIENTS WITH LOCALIZED PROSTATE CANCER: A POPULATION-BASED ANALYSIS
    Tran, Vicki
    Martell, Kevin
    Husain, Siraj
    Sia, Michael
    Quirk, Sarah
    Schinkel, Colleen
    Heikal, Amr
    Afzal, Arfan
    Lu, Shuang
    Abedin, Tasnima
    Quon, Harvey
    [J]. RADIOTHERAPY AND ONCOLOGY, 2020, 150 : S72 - S72
  • [3] Rates of primary and secondary treatments for patients on active surveillance for localized prostate cancer-A population-based cohort study
    Matta, Rano
    Hird, Amanda E.
    Dvorani, Erind
    Saskin, Refik
    Nason, Gregory J.
    Kulkarni, Girish
    Kodama, Ronald T.
    Herschorn, Sender
    Nam, Robert K.
    [J]. CANCER MEDICINE, 2020, 9 (19): : 6946 - 6953
  • [4] Early mortality of prostatectomy vs. radiotherapy as a primary treatment for prostate cancer: a population-based study
    Medenwald, D.
    Vordermark, D.
    Dietzel, C.
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2019, 195 : S153 - S153
  • [5] Age dependence of modern clinical risk groups for localized prostate cancer-A population-based study
    Minh-Phuong Huynh-Le
    Myklebust, Tor Age
    Feng, Christine H.
    Karunamuni, Roshan
    Johannesen, Tom Borge
    Dale, Anders M.
    Andreassen, Ole A.
    Seibert, Tyler M.
    [J]. CANCER, 2020, 126 (08) : 1691 - 1699
  • [6] Competing-Risks Mortality After Radiotherapy vs. Observation for Localized Prostate Cancer: A Population-based Study
    Abdollah, Firas
    Sun, Maxine
    Schmitges, Jan
    Thuret, Rodolphe
    Tian, Zhe
    Shariat, Shahrokh F.
    Briganti, Alberto
    Jeldres, Claudio
    Perrotte, Paul
    Montorsi, Francesco
    Karakiewicz, Pierre I.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (01): : 95 - 103
  • [7] Risk of primary lung cancer after adjuvant radiotherapy in breast cancer-a large population-based study
    Wennstig, Anna-Karin
    Wadsten, Charlotta
    Garmo, Hans
    Johansson, Mikael
    Fredriksson, Irma
    Blomqvist, Carl
    Holmberg, Lars
    Nilsson, Greger
    Sund, Malin
    [J]. NPJ BREAST CANCER, 2021, 7 (01)
  • [8] RADIOTHERAPY AND SURVIVAL IN PROSTATE CANCER PATIENTS: A POPULATION-BASED STUDY
    Zhou, Esther H.
    Ellis, Rodney T.
    Cherullo, Edward
    Colussi, Valdir
    Xu, Fang
    Chen, Wei-Dong
    Gupta, Sanjay
    Whalen, Christopher C.
    Bodner, Donald
    Resnick, Martin I.
    Rimm, Alfred A.
    Koroukian, Siran M.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 73 (01): : 15 - 23
  • [9] Management outcomes of localized low-risk prostate cancer: A population-based study.
    Mao, Shifeng S.
    Yin, Yue
    Wegner, Rodney E.
    Ramirez, Angela M. Sanguino
    Lyne, John
    Miller, Ralph
    Cohen, Jeffrey
    Samiei, Arash
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [10] Safety of image-guided radiotherapy in definitive radiotherapy for localized prostate cancer: a population-based analysis
    Kuo, Yao-Hung
    Liang, Ji-An
    Chen, Guan-Heng
    Li, Chia-Chin
    Chien, Chun-Ru
    [J]. BRITISH JOURNAL OF RADIOLOGY, 2021, 94 (1121):